| Joseph Nezgoda, M D | |
|
1411 N Flagler Dr Ste 4000, West Palm Beach, FL 33401-3411 | |
| (561) 832-6113 | |
| (888) 366-1852 |
| Full Name | Joseph Nezgoda |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 16 Years |
| Location | 1411 N Flagler Dr Ste 4000, West Palm Beach, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1861643629 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | ME124278 (Florida) | Secondary |
| 207WX0107X | Ophthalmology - Retina Specialist | ME124278 (Florida) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| South Florida Eye Institute, Inc. | 4981613080 | 6 |
| Eye Of Horus Pa | 4981636495 | 3 |
| Andre J Golino Md And Associates Pa | 8729073531 | 2 |
| Glaucoma Specialists Of South Florida Pa | 9830378918 | 3 |
News Archive
Quick-Med Technologies, Inc. announced today the development of a new prototype wound dressing, NIMBUS® Advanced Active, developed as part of ongoing research currently being funded by the U.S. Army Medical Research and Material Command under a $900,000 Small Business Innovation Research (SBIR) grant. NIMBUS was competitively selected by the U.S. Army for evaluation in the healing of vesicant injuries, and this new dressing is the first "active" wound healing product developed by Quick-Med.
A popular aquarium fish may hold answers to how tumors form in a childhood cancer.
With greater water scarcity in some regions and increasing global demand for high quality water, international trade agreements need to help save water globally. This was the main conclusion of a special report, published by the UNESCO-IHE Institute for Water Education.
To the surprise of researchers at Mayo Clinic who led a national clinical trial, a targeted therapy that provides benefit to patients with metastatic colon cancer has failed to help patients with less advanced, stage III cancer. In fact, patients who used the agent, cetuximab, with chemotherapy had outcomes slightly inferior to patients treated with chemotherapy alone.
Researchers from NeuroPhage Pharmaceuticals, Inc. have engineered a series of molecules with the potential to treat most neurodegenerative diseases that are characterized by misfolded proteins, such as Alzheimer's, Parkinson's and Huntington's diseases.
› Verified 4 days ago
| Entity Name | Andre J Golino Md And Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730150715 PECOS PAC ID: 8729073531 Enrollment ID: O20040419001790 |
News Archive
Quick-Med Technologies, Inc. announced today the development of a new prototype wound dressing, NIMBUS® Advanced Active, developed as part of ongoing research currently being funded by the U.S. Army Medical Research and Material Command under a $900,000 Small Business Innovation Research (SBIR) grant. NIMBUS was competitively selected by the U.S. Army for evaluation in the healing of vesicant injuries, and this new dressing is the first "active" wound healing product developed by Quick-Med.
A popular aquarium fish may hold answers to how tumors form in a childhood cancer.
With greater water scarcity in some regions and increasing global demand for high quality water, international trade agreements need to help save water globally. This was the main conclusion of a special report, published by the UNESCO-IHE Institute for Water Education.
To the surprise of researchers at Mayo Clinic who led a national clinical trial, a targeted therapy that provides benefit to patients with metastatic colon cancer has failed to help patients with less advanced, stage III cancer. In fact, patients who used the agent, cetuximab, with chemotherapy had outcomes slightly inferior to patients treated with chemotherapy alone.
Researchers from NeuroPhage Pharmaceuticals, Inc. have engineered a series of molecules with the potential to treat most neurodegenerative diseases that are characterized by misfolded proteins, such as Alzheimer's, Parkinson's and Huntington's diseases.
› Verified 4 days ago
| Entity Name | Florida Eye Microsurgical Institute Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104971423 PECOS PAC ID: 2163498296 Enrollment ID: O20040909000326 |
News Archive
Quick-Med Technologies, Inc. announced today the development of a new prototype wound dressing, NIMBUS® Advanced Active, developed as part of ongoing research currently being funded by the U.S. Army Medical Research and Material Command under a $900,000 Small Business Innovation Research (SBIR) grant. NIMBUS was competitively selected by the U.S. Army for evaluation in the healing of vesicant injuries, and this new dressing is the first "active" wound healing product developed by Quick-Med.
A popular aquarium fish may hold answers to how tumors form in a childhood cancer.
With greater water scarcity in some regions and increasing global demand for high quality water, international trade agreements need to help save water globally. This was the main conclusion of a special report, published by the UNESCO-IHE Institute for Water Education.
To the surprise of researchers at Mayo Clinic who led a national clinical trial, a targeted therapy that provides benefit to patients with metastatic colon cancer has failed to help patients with less advanced, stage III cancer. In fact, patients who used the agent, cetuximab, with chemotherapy had outcomes slightly inferior to patients treated with chemotherapy alone.
Researchers from NeuroPhage Pharmaceuticals, Inc. have engineered a series of molecules with the potential to treat most neurodegenerative diseases that are characterized by misfolded proteins, such as Alzheimer's, Parkinson's and Huntington's diseases.
› Verified 4 days ago
| Entity Name | Eye Of Horus Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164421418 PECOS PAC ID: 4981636495 Enrollment ID: O20050906000861 |
News Archive
Quick-Med Technologies, Inc. announced today the development of a new prototype wound dressing, NIMBUS® Advanced Active, developed as part of ongoing research currently being funded by the U.S. Army Medical Research and Material Command under a $900,000 Small Business Innovation Research (SBIR) grant. NIMBUS was competitively selected by the U.S. Army for evaluation in the healing of vesicant injuries, and this new dressing is the first "active" wound healing product developed by Quick-Med.
A popular aquarium fish may hold answers to how tumors form in a childhood cancer.
With greater water scarcity in some regions and increasing global demand for high quality water, international trade agreements need to help save water globally. This was the main conclusion of a special report, published by the UNESCO-IHE Institute for Water Education.
To the surprise of researchers at Mayo Clinic who led a national clinical trial, a targeted therapy that provides benefit to patients with metastatic colon cancer has failed to help patients with less advanced, stage III cancer. In fact, patients who used the agent, cetuximab, with chemotherapy had outcomes slightly inferior to patients treated with chemotherapy alone.
Researchers from NeuroPhage Pharmaceuticals, Inc. have engineered a series of molecules with the potential to treat most neurodegenerative diseases that are characterized by misfolded proteins, such as Alzheimer's, Parkinson's and Huntington's diseases.
› Verified 4 days ago
| Entity Name | South Florida Eye Institute, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073542650 PECOS PAC ID: 4981613080 Enrollment ID: O20060418000733 |
News Archive
Quick-Med Technologies, Inc. announced today the development of a new prototype wound dressing, NIMBUS® Advanced Active, developed as part of ongoing research currently being funded by the U.S. Army Medical Research and Material Command under a $900,000 Small Business Innovation Research (SBIR) grant. NIMBUS was competitively selected by the U.S. Army for evaluation in the healing of vesicant injuries, and this new dressing is the first "active" wound healing product developed by Quick-Med.
A popular aquarium fish may hold answers to how tumors form in a childhood cancer.
With greater water scarcity in some regions and increasing global demand for high quality water, international trade agreements need to help save water globally. This was the main conclusion of a special report, published by the UNESCO-IHE Institute for Water Education.
To the surprise of researchers at Mayo Clinic who led a national clinical trial, a targeted therapy that provides benefit to patients with metastatic colon cancer has failed to help patients with less advanced, stage III cancer. In fact, patients who used the agent, cetuximab, with chemotherapy had outcomes slightly inferior to patients treated with chemotherapy alone.
Researchers from NeuroPhage Pharmaceuticals, Inc. have engineered a series of molecules with the potential to treat most neurodegenerative diseases that are characterized by misfolded proteins, such as Alzheimer's, Parkinson's and Huntington's diseases.
› Verified 4 days ago
| Entity Name | Glaucoma Specialists Of South Florida Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629388558 PECOS PAC ID: 9830378918 Enrollment ID: O20110120001182 |
News Archive
Quick-Med Technologies, Inc. announced today the development of a new prototype wound dressing, NIMBUS® Advanced Active, developed as part of ongoing research currently being funded by the U.S. Army Medical Research and Material Command under a $900,000 Small Business Innovation Research (SBIR) grant. NIMBUS was competitively selected by the U.S. Army for evaluation in the healing of vesicant injuries, and this new dressing is the first "active" wound healing product developed by Quick-Med.
A popular aquarium fish may hold answers to how tumors form in a childhood cancer.
With greater water scarcity in some regions and increasing global demand for high quality water, international trade agreements need to help save water globally. This was the main conclusion of a special report, published by the UNESCO-IHE Institute for Water Education.
To the surprise of researchers at Mayo Clinic who led a national clinical trial, a targeted therapy that provides benefit to patients with metastatic colon cancer has failed to help patients with less advanced, stage III cancer. In fact, patients who used the agent, cetuximab, with chemotherapy had outcomes slightly inferior to patients treated with chemotherapy alone.
Researchers from NeuroPhage Pharmaceuticals, Inc. have engineered a series of molecules with the potential to treat most neurodegenerative diseases that are characterized by misfolded proteins, such as Alzheimer's, Parkinson's and Huntington's diseases.
› Verified 4 days ago
| Entity Name | Retina Macula Institute, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134832827 PECOS PAC ID: 2264898493 Enrollment ID: O20230515000767 |
News Archive
Quick-Med Technologies, Inc. announced today the development of a new prototype wound dressing, NIMBUS® Advanced Active, developed as part of ongoing research currently being funded by the U.S. Army Medical Research and Material Command under a $900,000 Small Business Innovation Research (SBIR) grant. NIMBUS was competitively selected by the U.S. Army for evaluation in the healing of vesicant injuries, and this new dressing is the first "active" wound healing product developed by Quick-Med.
A popular aquarium fish may hold answers to how tumors form in a childhood cancer.
With greater water scarcity in some regions and increasing global demand for high quality water, international trade agreements need to help save water globally. This was the main conclusion of a special report, published by the UNESCO-IHE Institute for Water Education.
To the surprise of researchers at Mayo Clinic who led a national clinical trial, a targeted therapy that provides benefit to patients with metastatic colon cancer has failed to help patients with less advanced, stage III cancer. In fact, patients who used the agent, cetuximab, with chemotherapy had outcomes slightly inferior to patients treated with chemotherapy alone.
Researchers from NeuroPhage Pharmaceuticals, Inc. have engineered a series of molecules with the potential to treat most neurodegenerative diseases that are characterized by misfolded proteins, such as Alzheimer's, Parkinson's and Huntington's diseases.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Joseph Nezgoda, M D 1411 N Flagler Dr Ste 4000, West Palm Beach, FL 33401-3411 Ph: (561) 832-6113 | Joseph Nezgoda, M D 1411 N Flagler Dr Ste 4000, West Palm Beach, FL 33401-3411 Ph: (561) 832-6113 |
News Archive
Quick-Med Technologies, Inc. announced today the development of a new prototype wound dressing, NIMBUS® Advanced Active, developed as part of ongoing research currently being funded by the U.S. Army Medical Research and Material Command under a $900,000 Small Business Innovation Research (SBIR) grant. NIMBUS was competitively selected by the U.S. Army for evaluation in the healing of vesicant injuries, and this new dressing is the first "active" wound healing product developed by Quick-Med.
A popular aquarium fish may hold answers to how tumors form in a childhood cancer.
With greater water scarcity in some regions and increasing global demand for high quality water, international trade agreements need to help save water globally. This was the main conclusion of a special report, published by the UNESCO-IHE Institute for Water Education.
To the surprise of researchers at Mayo Clinic who led a national clinical trial, a targeted therapy that provides benefit to patients with metastatic colon cancer has failed to help patients with less advanced, stage III cancer. In fact, patients who used the agent, cetuximab, with chemotherapy had outcomes slightly inferior to patients treated with chemotherapy alone.
Researchers from NeuroPhage Pharmaceuticals, Inc. have engineered a series of molecules with the potential to treat most neurodegenerative diseases that are characterized by misfolded proteins, such as Alzheimer's, Parkinson's and Huntington's diseases.
› Verified 4 days ago
Nunzio P Sossi, M.D..PHD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 130 Butler St, West Palm Beach, FL 33407 Phone: 561-832-6113 Fax: 561-833-3003 | |
Steven Edens, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2000 Palm Beach Lakes Blvd Ste 400, West Palm Beach, FL 33409 Phone: 561-500-2020 | |
Mr. Salomon Emilio Melgen, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 2521 Metrocentre Blvd, West Palm Beach, FL 33407 Phone: 561-687-0007 Fax: 561-688-0431 | |
Mr. Norman C Johnson Jr., M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 1500 N Dixie Hwy, #200, West Palm Beach, FL 33401 Phone: 561-832-3774 Fax: 561-832-4082 | |
Dr. Michael Patipa, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 4461 Medical Center Way, Suite A, West Palm Beach, FL 33407 Phone: 561-845-6500 Fax: 561-845-6300 | |
Richard Michael Kadingo, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 1515 N Flagler Dr, Ste 500, West Palm Beach, FL 33401 Phone: 561-659-9700 Fax: 561-659-7153 | |
Jodi Ian Luchs, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1515 N Flagler Dr Ste 500, West Palm Beach, FL 33401 Phone: 561-659-9700 Fax: 561-659-7153 |